Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONUMENT study: Sequential monthly ibandronate after teriparatide in primary osteoporosis
jRCTs071180086Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ibandronate in involutional osteoporosis, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Primary endpoint: Change rate of lumbar spine bone mineral density at 12 months. Started Feb 2017; status: completed.
02
Drugs
ibandronate
03
Conditions
involutional osteoporosis
Beyond the preview
Go deeper on jRCTs071180086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180086.